Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $60.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 65.29% from the stock’s previous close.

A number of other analysts also recently weighed in on COLL. Needham & Company LLC cut their target price on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays reduced their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Finally, Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $53.40.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $36.30 on Friday. The company’s 50 day moving average price is $43.46 and its two-hundred day moving average price is $41.90. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $50.79. The firm has a market cap of $1.15 billion, a PE ratio of 21.23 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The business had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.77 earnings per share. Equities research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.51% of the stock is owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of COLL. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd grew its position in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the period. Hantz Financial Services Inc. raised its position in shares of Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 993 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $61,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.